Skip to main navigation Press Releases Items Per Page 10 Year 2021 DATE TITLE FILES Nov 18, 2021 Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference PDF Version Nov 04, 2021 Dynavax Reports Third Quarter 2021 Financial Results PDF Version Nov 02, 2021 Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version Oct 21, 2021 Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman PDF Version Oct 21, 2021 Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021 PDF Version Oct 18, 2021 Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version Oct 18, 2021 COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial PDF Version Oct 04, 2021 Dynavax and U.S. Department of Defense Announce Collaboration to Develop an Adjuvanted Plague Vaccine Using Dynavax's CpG 1018 Adjuvant PDF Version Oct 01, 2021 Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version Sep 27, 2021 Dynavax to Present at Upcoming Investment Conferences PDF Version PAGINATION Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page next › Last page last » Email Alerts RSS Print Share Search ABOUT PRODUCT SCIENCE PORTFOLIO ONGOING STUDIES CAREERS CONTACT © 2021 Dynavax Technologies. All rights reserved. Website Design: Hane Chow, Inc.